Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

NIH Scientist Pleads Guilty

Trey Sunderland admits to engaging in conflict of interest activities

by Susan R. Morrissey
December 13, 2006

Pearson (Trey) Sunderland III pled guilty on Dec. 8 to charges that he committed a conflict-of-interest violation by improperly accepting nearly $300,000 in consulting fees and other expenses from the drug company Pfizer. The former chief of the now-disbanded Geriatric Psychiatry Branch of the National Institute of Mental Health avoided a possible one-year prison term by accepting a plea agreement.

In entering his plea, Sunderland admitted to accepting consulting fees and travel expenses from Pfizer without getting prior permission from the National Institutes of Health or disclosing it to the agency. The research involved dealt with the onset and progression of Alzheimer's disease.

As part of the agreement, Sunderland will face two years of probation, will be forced to forfeit the $300,000 of income and expense reimbursements stemming from his inappropriate consulting activities, and will have to do 400 hours of community service. In addition, he will also be fined an amount to be determined at his sentencing on Dec. 22.

The guilty plea comes two years after conflict-of-interest allegations first surfaced concerning NIH scientists. Since that time, Congress has held several hearings dealing with ethics at NIH. For its part, NIH instituted tougher new conflict-of-interest rules that, among other things, ban consulting with drug companies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.